Dermata Therapeutics : Corporate Presentation 2025

About this update from Dermata Therapeutics, Inc.

Dermata Therapeutics Transforming Topical Treatment of the Skin Corporate Presentation 2025 Corporate Highlights Unique, multi-use topical platform technology utilizing multiple mechanisms of actions Pipeline addressing large medical and aesthetic dermatology market opportunities Lead program with compelling Phase 2b clinical data for once-weekly topical treatment of acne Xyngari Acne - STAR-1 Phase 3 - Statistically Significant Once-weekly topical application Positive STAR-1 Phase 3 study STAR-2 Phase 3 study to begin in 2025 Psoriasis - Positive Phase 1b Completed Inhibits inflammatory cytokines IL-17A & IL-17F in vitro Reduced lesion size after 8 weeks DMT410 Hyperhidrosis - Phase 2a planned with DAXXIFY Phase 1 POC completed with BOTOX Topical delivery of botulinum toxin to the dermis 75% reduction in gravimetric sweat production Aesthetics - Phase 1b PoC Completed Clinical improvement in aesthetic appearance seen Pore Size Fine Lines Melasma Sebum production Experienced Management Team and Board Senior Management Gerry Proehl Chairman, President, and CEO Kyri Van Hoose, C.P.A., MBA SVP, Chief Financial Officer Maria Bedoya Toro Munera, Ph.D. SVP, Regulatory Affairs & Quality Assurance Chris Nardo, M.P.H., Ph.D. SVP, Chief Development Officer Board of Directors Gerry Proehl Wendell Wierenga Ph.D. Steven J. Mento, Ph.D. Andrew Sandler, M.D. David Hale Kathleen Scott Mary Fischer Brittany Bradrick Market Opportunities in Dermatology Xyngari/DMT410 - Acne US Prevalence ~50M Market Size ~$2.3B 2 DMT410 - Aesthetics ~13.1M (procedures) ~$12B 5 DMT410 - Hyperhidrosis ~2M (diagnosed) ~$281M 4 Opportunity Highlights 85% of teenagers experience some form of acne 1 Few new novel topical treatment options Most new products are reformulations and dosed QD or BID Almost 9.5 million procedures with neuromodulators 3 Average cost of one session is $435 3 Untapped markets where neuromodulators are rarely used BOTOX® injections expected to be 40% of the overall market. Growing demand for hyperhidrosis treatments , especially with increasing disease awareness - Guideline for Care and Management of Acne - IQVIA, Inc. Top Line Market and Sales Analysis from years 2015-2020 - 2023 Plastic Surgery Statistics Report - GlobalData Axillary Hyperhidrosis: opportunity Assessment and Forecast to 2030 5- Stifl Dermatology Healthcare Market Overview Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Dermata Therapeutics, Inc.